Summary:
A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
Qualified Participants Must:
Be 18-64 Years old
Diagnosed with Schizophrenia
Qualified Participants May Receive:
Compensation for time and travel